Adolescents, Young Adults, and Psychedelic-Assisted Therapy in Canada — Considerations and Caveats

Adolescents (under 18) and young adults (18–25) carry substantial mental health need — depression, anxiety, post-traumatic stress disorder, obsessive-compulsive disorder, and eating disorders. Mental illness in young people is a public health priority in Canada. Yet the pivotal psychedelic-assisted therapy RCT base explicitly excludes patients under 18, brain development continues to approximately age 25, and the long-term safety of psychedelic-assisted therapy in the developing brain is unknown. This article is a Canadian safety and caveat hub for what the evidence does — and does not — support in adolescents and young adults: specialized pediatric mental health care first-line, Spravato is not approved for under 18, published adolescent RCTs in psychedelic-assisted therapy are limited or absent, and ATMA CENA works with adult populations — adolescent patients with depression, PTSD, OCD, eating disorders, or treatment-resistant depression should be in specialized adolescent care. Honest framing: comprehensive family/caregiver involvement is non-negotiable, crisis resources are foundational (Kids Help Phone 1-800-668-6868; 9-8-8 Canada Suicide Crisis Helpline), and chronological age alone is not the sole determinant for young adults — brain development, clinical complexity, and care setting all matter.

Key takeaways

• Most psychedelic-assisted therapy RCTs explicitly exclude patients under 18. Goodwin 2022, Carhart-Harris 2021, Mitchell 2021/2023, Anand 2023 ELEKT-D all enrolled adults only.
• Brain development continues to approximately age 25 — long-term safety of psychedelic-assisted therapy in the developing brain is unknown.
• ATMA CENA works with adult populations. Adolescent patients with depression, PTSD, OCD, eating disorders, or treatment-resistant illness should be in specialized adolescent care.
• Specialized pediatric mental health care first-line — SickKids (Toronto), CHEO (Ottawa), BC Children's (Vancouver), Sainte-Justine (Montreal), Stollery (Edmonton), Alberta Children's (Calgary), IWK (Halifax), and provincial adolescent mental health services.
• Adolescent depression first-line: CBT, IPT, family therapy, and fluoxetine (the only SSRI with Health Canada pediatric depression approval) — CANMAT pediatric mood disorder framing.
• Adolescent PTSD first-line: trauma-focused CBT, EMDR.
• Adolescent OCD first-line: family-based ERP (exposure and response prevention).
• Adolescent eating disorders first-line: family-based therapy (FBT/Maudsley) — foundational.
• Spravato is NOT approved for under 18 in Canada. Black-box / serious-warnings on antidepressants under 25 applies to esketamine.
• Ketamine in adolescents: very limited published evidence — Cullen 2018 and Dwyer 2017 are the principal early signals.
• Psilocybin and MDMA in adolescents: NO published adolescent RCTs. SAP applications for adolescents would face significant clinical resistance.
• Young adults (18–25): inclusion in adult RCTs varies; brain still developing; comprehensive psychiatric assessment and family involvement remain meaningful.
• Family involvement is non-negotiable for adolescent patients.
• Provincial age-of-consent for medical decisions varies — Quebec age 14 with specific framing; other provinces use Mature Minor / Gillick competence.
• Crisis resources first: Kids Help Phone 1-800-668-6868 (text 686868); 9-8-8 Canada Suicide Crisis Helpline.

Why adolescents and young adults are a distinct clinical population

Adolescence and young adulthood are developmental periods, not just chronological ones. Specific clinical features:

• Brain development continues to ~25 — prefrontal cortex maturation (executive function, impulse control, emotional regulation) is not complete until the mid-20s. Long-term effects of psychedelic exposure on the developing brain are unknown.
• Identity formation, peer attachment, and family individuation are core developmental tasks; mental health interventions in this period have lifelong consequences.
• First-onset mental illness — most lifetime psychiatric disorders begin before age 25 (Kessler et al.). Early intervention is high-leverage.
• Suicide is the leading or near-leading cause of death in Canadian adolescents and young adults (Statistics Canada / Public Health Agency of Canada). Crisis safety is foundational.
• Family system is the care unit — adolescent care is family-involving by clinical necessity, not just preference.
• School and developmental functioning — treatment must integrate with school, family, and emerging-adult life trajectories.

Specialized pediatric and adolescent mental health pathways in Canada

Adolescent mental health care in Canada is delivered through specialized pediatric centres, provincial child and youth mental health services, family physicians, community pediatricians, and child and adolescent psychiatrists. Primary pathways:

• The Hospital for Sick Children (SickKids) — Toronto: specialized child and adolescent psychiatry, eating disorders program, OCD program
• Children's Hospital of Eastern Ontario (CHEO) — Ottawa: child and youth mental health programs
• BC Children's Hospital — Vancouver: provincial adolescent mental health, eating disorders
• CHU Sainte-Justine — Montreal: pediatric psychiatry, adolescent mood and anxiety
• Stollery Children's Hospital — Edmonton: child and adolescent mental health
• Alberta Children's Hospital — Calgary: child and adolescent mental health
• IWK Health Centre — Halifax: Maritime pediatric mental health
• Provincial child and youth mental health teams — community-based programs in every province
• Schools and school-based mental health — increasingly important access point

For adolescents with treatment-resistant illness, specialized pediatric tertiary programs are the appropriate setting — not adult psychedelic-assisted therapy clinics.

First-line treatments — adolescents

Adolescent mental health first-line treatments are well-established and have substantial evidence bases. CANMAT pediatric mood disorder guidelines, AACAP practice parameters, and CADTH/INESSS reviews provide standard-of-care framing.

Adolescent depression

• Cognitive behavioural therapy (CBT) — first-line; substantial RCT evidence
• Interpersonal therapy for adolescents (IPT-A) — first-line; particularly effective in mid-to-late adolescence
• Family therapy — adjunctive or primary depending on context
• Fluoxetine — the only SSRI with Health Canada pediatric depression approval; first-line pharmacotherapy
• Combined CBT + fluoxetine — TADS study showed superior outcomes for severe adolescent depression
• Sertraline, escitalopram — used off-label with caution in adolescent depression where fluoxetine inadequate

Adolescent PTSD

• Trauma-focused CBT (TF-CBT) — first-line; gold-standard adolescent PTSD treatment
• EMDR (Eye Movement Desensitization and Reprocessing) — established adolescent evidence
• Cognitive Processing Therapy (adolescent adaptations) — emerging evidence

Adolescent OCD

• Exposure and response prevention (ERP), family-based — first-line; substantial adolescent evidence (POTS study)
• CBT with ERP — combined modality
• Sertraline, fluoxetine — first-line pharmacotherapy where SSRI indicated

Adolescent eating disorders

• Family-based therapy (FBT / Maudsley) — first-line for adolescent anorexia nervosa; substantial RCT evidence (Lock & Le Grange)
• CBT-E (enhanced) — for older adolescents with bulimia nervosa or EDNOS
• Specialized pediatric eating disorders programs — SickKids, BC Children's, Sainte-Justine, Stollery, Alberta Children's all have eating disorders services

These first-line pathways are foundational and must be exhausted (or running concurrently with specialized care) before any consideration of off-label or investigational interventions.

For more detail, see Eating Disorders and Psychedelic-Assisted Therapy, PTSD and Psychedelic-Assisted Therapy.

The adolescent psychedelic-assisted therapy evidence map — what we have and don't have

Spravato (esketamine) — NOT approved for under 18 in Canada

Spravato (esketamine) is Health Canada-approved for treatment-resistant depression in adults only. The product monograph specifies adult use; under-18 use is not authorized. The black-box / serious warning on antidepressants regarding suicidality in patients under 25 applies to esketamine — this is a longstanding regulatory concern that drives caution in the adolescent and young-adult population.

For more detail, see Spravato Coverage and Pathways.

Off-label ketamine in adolescents — very limited evidence

Published adolescent ketamine evidence is limited and early-stage:

• Cullen KR, Amatya P, Roback MG, et al. 2018 — open-label study of IV ketamine in adolescent treatment-resistant depression at the University of Minnesota; signals of acute antidepressant response in a small adolescent TRD sample; no controlled comparison.
• Dwyer JB, Beyer C, Wilkinson ST, et al. 2017 — case series and review framing of adolescent ketamine for TRD; emphasizes the absence of large-scale RCT evidence and the importance of specialized adolescent psychiatry context.
• Subsequent literature: small open-label studies and case series have continued; large RCTs in adolescent populations have not yet been completed.

Implications: ketamine in adolescents is investigational, should be delivered in specialized adolescent psychiatric settings (typically tertiary pediatric centres or research protocols), not adult outpatient KAP (ketamine-assisted psychotherapy) clinics, and requires comprehensive family involvement, careful suicidality safety planning, and oversight from a child and adolescent psychiatrist.

Psilocybin in adolescents — NO published RCTs

There are no published randomized controlled trials of psilocybin-assisted therapy in adolescents. The pivotal psilocybin trials — Goodwin 2022 COMP001 NEJM TRD, Carhart-Harris 2021 NEJM MDD, Griffiths 2016 / Ross 2016 end-of-life distress, Davis 2021 MDD — all enrolled adults only. The MAGNUS phase 3 trials continue to enrol adults only.

Implications: psilocybin in adolescents is investigational with no published controlled evidence. Health Canada Special Access Program (SAP) applications for adolescents would face significant clinical resistance — SAP requires absence of alternative treatments and evidence base for the specific indication, and the pediatric/adolescent evidence base is essentially absent. ATMA CENA does not support psilocybin SAP applications for adolescent patients.

For more detail, see Psilocybin Therapy in Canada.

MDMA in adolescents — NO published RCTs

There are no published randomized controlled trials of MDMA-assisted therapy in adolescents. The pivotal MDMA-AT trials — Mitchell 2021/2023 MAPP1/MAPP2 NEJM/Nature Medicine PTSD, Mithoefer 2018, and predecessor MAPS trials — all enrolled adults (18+).

Implications: MDMA in adolescents is investigational with no published controlled evidence. SAP applications for adolescents would face the same significant clinical resistance.

Young adults (18–25) — adult RCT inclusion varies

Young adults aged 18–25 are technically adults under Canadian medical and regulatory frameworks. Adult psychedelic-assisted therapy RCTs include 18+:

• Goodwin 2022 COMP001 — psilocybin TRD; included 18+
• Mitchell 2021/2023 MAPP1/MAPP2 — MDMA-AT PTSD; included 18+
• Anand 2023 ELEKT-D — ketamine vs ECT TRD; included 18+
• Spravato pivotal program — adults 18+; majority older but young adults included

However, brain development continues to ~25, and the young-adult inclusion in trials does not specifically address developmental considerations. Comprehensive psychiatric assessment and meaningful family involvement remain clinically appropriate for young adults.

Decision framework — adolescents and young adults

Adolescents (under 18)

Young adults (18–25)

Provincial age-of-consent considerations

Canadian medical decision-making consent law for minors varies:

• Quebec: Civil Code Article 14 allows persons aged 14+ to consent to medical care on their own; specific framing for "care not required by state of health" and consent withdrawal involves additional considerations
• Other provinces: most apply the Mature Minor doctrine / Gillick competence — capacity-based assessment rather than fixed age. A capable minor can consent; the threshold depends on the complexity and risk of the intervention
• Substitute decision-makers play a role where the minor lacks capacity
• For investigational treatments and complex interventions like psychedelic-assisted therapy, even capable minors are appropriately routed through family-involving and specialized-care pathways

Crisis resources — foundational

If you or a young person you know is in crisis:

• 9-8-8 Canada Suicide Crisis Helpline — call or text 9-8-8 (24/7, all of Canada)
• Kids Help Phone — 1-800-668-6868 (24/7, ages 5–29); text CONNECT to 686868; live chat at https://kidshelpphone.ca/
• Hospital emergency department — for any acute safety concern
• Provincial mental health crisis lines — every province has a 24/7 crisis line
• Local police 911 — if life-threatening emergency
• First Nations and Inuit Hope for Wellness Helpline: 1-855-242-3310 (24/7, multilingual including Cree, Ojibway, Inuktitut)

These resources are foundational; psychedelic-assisted therapy is never an emergency intervention.

Family and caregiver involvement — non-negotiable for adolescents

Adolescent mental health care is inherently family-involving:

• Family-based therapy (FBT/Maudsley) for adolescent anorexia is the foundational treatment paradigm
• Family therapy is integral to adolescent depression and anxiety care
• Caregiver psychoeducation is part of every standard pediatric mental health pathway
• Consent and decision-making typically include parental/guardian involvement even where capable-minor consent applies
• Safety planning requires family awareness and engagement

For young adults (18–25), family involvement is strongly clinically recommended even where not strictly required for consent — particularly in conditions associated with high suicidality, eating disorders, OCD, and complex PTSD.

For more detail, see Family Members and Loved Ones Guide.

What the evidence does NOT say

• No psychedelic-assisted therapy is approved for adolescents (under 18) in Canada. Spravato is not approved under 18.
• No published randomized controlled trial supports psilocybin or MDMA-assisted therapy in adolescents.
• Ketamine evidence in adolescents is very limited — Cullen 2018 and Dwyer 2017 are early signals, not pivotal evidence.
• Spravato carries the under-25 black-box / serious-warnings on antidepressants regarding suicidality.
• Brain development to ~25 means even young-adult inclusion in adult trials does not specifically address developmental considerations.
• Specialized pediatric mental health care is the foundation — first-line evidence-based treatments must be adequately trialled.
• Family involvement is foundational — adolescent care without family engagement is not standard-of-care.
• SAP applications for adolescents would face significant clinical resistance — SAP requires evidence base and absence of alternatives; the adolescent evidence base is essentially absent.
• Eating disorders specifically: family-based therapy (FBT/Maudsley) is foundational; psychedelic-assisted therapy in adolescent eating disorders has no published controlled evidence.

How ATMA CENA works with adolescents and young adults

ATMA CENA works with adult populations. Adolescent patients (under 18) are referred to specialized adolescent mental health care — typically through their family physician, pediatrician, or community child and youth mental health team, with onward referral to tertiary pediatric programs (SickKids, CHEO, BC Children's, Sainte-Justine, Stollery, Alberta Children's, IWK) where indicated.

For young adults (18–25):

• Comprehensive intake: full psychiatric assessment with explicit developmental framing; family/support system mapping; suicidality and crisis-resource grounding
• First-line treatment review: confirmation that evidence-based first-line treatments have been adequately trialled
• Family involvement: strongly recommended; integration support throughout preparation, dosing day, and integration where applicable
• Honest framing: developmental considerations, RCT inclusion limits, and brain-development context discussed explicitly
• Care coordination: with family physician, psychiatrist, psychotherapist, and where applicable specialty clinic
• Crisis resources foundational: Kids Help Phone (up to age 29), 9-8-8, provincial crisis lines
• No psilocybin/MDMA SAP for adolescents: ATMA CENA does not support psilocybin or MDMA SAP applications for adolescent (under-18) patients

For more detail, see Treatment-Resistant Depression and Psychedelic-Assisted Therapy, PTSD and Psychedelic-Assisted Therapy, Suicidality and Psychedelic-Assisted Therapy, Bipolar Disorder and Psychedelic-Assisted Therapy — Considerations.

Frequently asked questions

Can my teenager (under 18) do ketamine therapy? Adolescent ketamine is investigational with very limited published evidence (Cullen 2018, Dwyer 2017). It should be delivered, if at all, in specialized adolescent psychiatric settings — tertiary pediatric centres or research protocols — not adult outpatient KAP clinics. ATMA CENA does not provide ketamine therapy to patients under 18.

Can my teenager do Spravato? No. Spravato is not approved for under 18 in Canada. The black-box / serious-warnings on antidepressants regarding suicidality under 25 applies.

Can my teenager do psilocybin therapy? There are no published RCTs of psilocybin in adolescents. SAP applications for adolescents would face significant clinical resistance. ATMA CENA does not support psilocybin SAP applications for adolescent patients.

Can my teenager do MDMA-assisted therapy? There are no published RCTs of MDMA-AT in adolescents. Same constraints as psilocybin apply.

My 17-year-old has treatment-resistant depression. What's the pathway? Specialized adolescent mental health care: a child and adolescent psychiatrist, ideally connected to a tertiary pediatric program (SickKids, CHEO, BC Children's, Sainte-Justine, Stollery, Alberta Children's, IWK). First-line treatments include CBT, IPT, family therapy, and fluoxetine. ECT is rarely used in adolescents but is available in tertiary settings for severe TRD. Investigational treatments would be considered only within specialized research or tertiary clinical contexts.

My 19-year-old wants to try psilocybin. What should we know? Young adults (18+) are technically adults and can pursue adult treatment pathways. Considerations: brain development continues to ~25; comprehensive psychiatric assessment and confirmation that first-line treatments have been adequately trialled; meaningful family involvement; explicit suicidality assessment (under-25 black-box considerations); honest framing of evidence base.

What about young adults aged 18–25? Adult RCTs typically include 18+; young adults are eligible for adult psychedelic-assisted therapy pathways with appropriate clinical assessment. Brain development considerations and family involvement remain meaningful. ATMA CENA's young-adult intake includes explicit developmental framing.

My adolescent has an eating disorder. Is psychedelic-assisted therapy appropriate? No — first-line care is family-based therapy (FBT/Maudsley), delivered through specialized pediatric eating disorders programs (SickKids, BC Children's, Sainte-Justine, Stollery, Alberta Children's). Adolescent eating disorder psychedelic-assisted therapy has no published controlled evidence.

My adolescent has PTSD. Is psychedelic-assisted therapy appropriate? First-line is trauma-focused CBT or EMDR delivered through specialized adolescent trauma services. MDMA-AT for adolescent PTSD has no published RCT evidence and is not currently a recommended pathway.

My adolescent has OCD. Is psychedelic-assisted therapy appropriate? First-line is family-based ERP. Psychedelic-assisted therapy for adolescent OCD has no published controlled evidence.

What's the consent age for medical decisions? Quebec Civil Code Article 14 allows 14+ to consent to medical care; other provinces apply the Mature Minor / Gillick competence framework — capacity-based assessment. For investigational treatments like psychedelic-assisted therapy, family-involving pathways are clinically appropriate even where capable-minor consent applies.

What are crisis resources for young people in Canada? Kids Help Phone 1-800-668-6868 (text CONNECT to 686868; ages 5–29; 24/7); 9-8-8 Canada Suicide Crisis Helpline (call or text 9-8-8); hospital emergency department for acute safety; provincial 24/7 crisis lines; First Nations and Inuit Hope for Wellness Helpline 1-855-242-3310.

Why does ATMA CENA not work with adolescents? ATMA CENA works with adult populations because the evidence base, regulatory framework, and clinical infrastructure for psychedelic-assisted therapy are adult-focused. Adolescent care requires specialized pediatric/adolescent psychiatric expertise, family-system intervention, and integration with school and developmental contexts that are appropriately delivered in tertiary pediatric programs and provincial child and youth mental health services.

Sources

1. Cullen KR, Amatya P, Roback MG, et al. (2018). Intravenous Ketamine for Adolescents with Treatment-Resistant Depression: An Open-Label Study. Journal of Child and Adolescent Psychopharmacology, 28(7):437-444. PMID: 29630412.
2. Dwyer JB, Beyer C, Wilkinson ST, et al. (2017). Ketamine as a Treatment for Adolescent Depression: A Case Report. J Am Acad Child Adolesc Psychiatry, 56(4):352-354. PMID: 28335880.
3. Lock J, Le Grange D. (2019). Family-based treatment: Where are we and where should we be going to improve recovery in child and adolescent eating disorders. International Journal of Eating Disorders, 52(4):481-487. PMID: 30520532.
4. March JS, Silva S, Petrycki S, et al. (TADS Team) (2004). Fluoxetine, cognitive-behavioral therapy, and their combination for adolescents with depression: Treatment for Adolescents With Depression Study (TADS) randomized controlled trial. JAMA, 292(7):807-820. PMID: 15315995.
5. Pediatric OCD Treatment Study (POTS) Team. (2004). Cognitive-behavior therapy, sertraline, and their combination for children and adolescents with obsessive-compulsive disorder: the Pediatric OCD Treatment Study (POTS) randomized controlled trial. JAMA, 292(16):1969-76. PMID: 15507582.
6. Goodwin GM, Aaronson ST, Alvarez O, et al. (2022). Single-Dose Psilocybin for a Treatment-Resistant Episode of Major Depression. New England Journal of Medicine, 387(18):1637-1648. PMID: 36322843.
7. Mitchell JM, Bogenschutz M, Lilienstein A, et al. (2021). MDMA-assisted therapy for severe PTSD: a randomized, double-blind, placebo-controlled phase 3 study (MAPP1). Nature Medicine, 27(6):1025-1033. PMID: 33972795.
8. Health Canada — Spravato Product Monograph (under-18 not authorized; under-25 antidepressant warnings): https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=98903
9. CANMAT and CCMD Pediatric/Youth Mood Disorder Guidelines (Bennett K, Courtney D, Henderson J, et al. and related Canadian pediatric mood disorder reviews): https://www.canmat.org/
10. American Academy of Child and Adolescent Psychiatry (AACAP) Practice Parameters — Depression, Anxiety, OCD, PTSD: https://www.aacap.org/AACAP/Resources_for_Primary_Care/Practice_Parameters_and_Resource_Centers/
11. CADTH and INESSS reviews — adolescent mental health interventions: https://www.cadth.ca/ ; https://www.inesss.qc.ca/
12. Kids Help Phone: https://kidshelpphone.ca/ (1-800-668-6868; text CONNECT to 686868)
13. 9-8-8 Canada Suicide Crisis Helpline: https://988.ca/
14. Health Canada — Special Access Program: https://www.canada.ca/en/health-canada/services/drugs-health-products/special-access.html

Related articles

• Older Adults and Psychedelic-Assisted Therapy
• Family Members and Loved Ones Guide
• Eating Disorders and Psychedelic-Assisted Therapy — adolescent FBT/Maudsley framing
• Treatment-Resistant Depression and Psychedelic-Assisted Therapy
• PTSD and Psychedelic-Assisted Therapy — adolescent TF-CBT and EMDR framing
• Suicidality and Psychedelic-Assisted Therapy — under-25 black-box context
• Bipolar Disorder and Psychedelic-Assisted Therapy — Considerations
• Ketamine Therapy in Canada
• Psilocybin Therapy in Canada

Last updated: 2026-05-06